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Reports in haematology, transplantation medicine and rheumatology indicate that Rituximab, a B cell depleting 
therapy, increases the risk for Pneumocystis jiroveci pneumopathy. Patients with ANCA-associated vasculitis 
have an increased incidence of Pneumocystis jiroveci pneumopathy compared to other autoimmune diseases and 
Rituximab is often used to induce and maintain remission.  
Herein we present a case of a patient with granulomatosis with polyangiitis treated with Rituximab for relapse 
that developed Pneumocystis jiroveci pneumopathy 3 months after and we review the relevant literature to assess 
Pneumocystis jiroveci pneumopathy incidence and risks factors under Rituximab. We also discuss whether 
pneumocystis jiroveci screening before Rituximab and Pneumocystis jiroveci pneumopathy prophylaxis under 
Rituximab are indicated. 
Pneumocystis jiroveci colonization is found in 25% of patients with autoimmune diseases. However the 
association between colonization and Pneumocystis jiroveci pneumopathy development is not very strong. 
Pneumocystis jiroveci pneumopathy incidence in ANCA-associated vasculitis patients treated with Rituximab is 
found to be 1.2%. Therefore evidence and practice do not support the use of Pneumocystis jiroveci pneumopathy 
chemoprophylaxis in all ANCA-associated vasculitis patients receiving Rituximab. CD4 cell count cut-off does 
not work well in patients treated with Rituximab as it does not reflect T-cell impairment following B cell 
depletion. 
To help stratify the risk of both colonization and Pneumocystis jiroveci pneumopathy development, assessment 
of the patient’s net stat of immunodeficiency before administering Rituximab – including age, renal or lung 
involvement, previous infections due to T cell dysfunction, blood tests (lymphocytopenia, low CD4 cell count) 
and concomitant therapy – is warranted. 
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The incidence of Pneumocystis jiroveci pneumonia (PCP) is increased in patients with Granulomatosis with 
polyangiitis (GPA) and ANCA-associated vasculitis (AAV) compared with other connective tissue diseases 
(CTD) [1]. PCP usually has an acute onset (fever, dry cough and respiratory failure) and can be life-threatening 
with a mortality rate exceeding 30% [2,3]. Treatment with methotrexate [4], high-dose prednisolone [4] and 
cyclophosphamide [5] in association with lymphopenia increases the risk for PCP in GPA patients. While 
prophylaxis with trimethoprim-sulphamethoxazole (TMP-SMX) is effective [5,6], there are few formal 
recommendations. The use of PCP prophylaxis is recommended with prolonged daily systemic corticosteroid 
therapy - ≥20 mg of prednisolone daily for ≥ 1 month [2,7], while EULAR  encourages its use during 
Cyclophosphamide therapy in AAV [8]. 
Rituximab (RTX) is a B cell depleting drug, that is effective both for remission induction [9,10] and maintenance 
[11-14] in AAV patients. There are multiple reports of PCP developing in patients treated with RTX for 
haematological malignancies, solid organ transplantation and autoimmune diseases.  
Herein, we present a GPA patient who developed PCP 3 months after RTX treatment for relapse and discuss the 
literature regarding PCP prophylaxis strategies in AAV patients receiving RTX.  
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Case report (laboratory values in table 1) 
The patient, a man born in 1932, was diagnosed February 1999 with PR3-ANCA positive GPA with kidney, 
lung, sinus and skin involvement. Disease relapses occurred in July 2001 and April 2011. He was successfully 
treated with cyclophosphamide (CYC) intravenous pulse at diagnosis and at the first flare for a cumulative dose 
of 25g. He used methotrexate (MTX) from 1999 to 2001 and mycophenolate mofetil (MMF) from 2002 to 2011  
as subsequent remission maintenance therapy with a daily oral dose prednisolone of 5 mg. 
The patient had Herpes-zoster infection 8 months after he began with MMF and pneumonia in 2006, which both 
resolved. Serum CMV-IgM was positive at several occasions between 2004 and 2006 indicating possible CMV 
reactivation without any signs of infection. April 2011, while on MMF 1500 mg and prednisolone 5 mg daily, 
the patient relapsed with increased activity in both sinuses and lungs. He was treated with two 1-g infusions of 
RTX 2 weeks apart (rheumatoid arthritis protocol) in monotherapy in combination with methylprednisolone 125 
mg (without any additional IV methylprednisolone infusions). MMF was discontinued and the patient was 
discharged with a daily oral dose of prednisolone of 40 mg to be gradually tapered.  
July 2011, the patient became acutely febrile with night sweats while using prednisolone 15 mg daily without 
any other symptoms and signs. The patient received blind broad spectrum intravenous antibiotics without any 
clinical improvement. Absolute white cell count was 8.3x10^9/L with an absolute neutrophile count of 
6.8x10^9/L. Erythrocyte sedimentation rate was 45mm after the first hour and CRP was 55 mg/L. 
Immunophenotyping of lymphocytes showed undetectable B cells, low T cells and CD4 (respectively 
0.66x10^9/L and 0.16x10^9/L). Serum total immunoglobulins was 7.5g/L with mild decrease of IgG class (5.6 
g/L). PR3-ANCA titters (measured in 2 different laboratories) had increased since RTX treatment from 42 to 147 
UI/L. Serology and PCR were negative for CMV and EBV as well as serologies for HCV, HBV, HIV, 
toxoplasmosis and syphilis. Transthoracal ultrasonography was negative for endocarditis. Chest high resolution 
computed tomography showed patchy ground-glass opacities dominating in the right upper lobe and 
bronchoscopy with broncheoalveolar lavage identified Pneumocystis jiroveci both by immunofluorescence and 
by PCR. The patient recovered from PCP after being treated with a reduced dose of Trimethoprim-
sulfamethoxazole (TMP-SMX) 320 mg-1600mg bid for 21 days due to decreased renal function.  
January 2013, the patient was in remission for his GPA while treated with prednisolone 5 mg daily. The B cell 
count (0.02x10^9/L) was low and the CD4/CD8 ratio was still inverted. The patient still received secondary PCP 
chemoprophylaxis - TMP-SMX 160mg-800mg daily. 
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Discussion 
Pneumocystis jiroveci (PJ) is a low virulence organism and may be the result of a de novo infection (person-to-
person transmission) or reactivation from a latent state (primary infection occurs early in life) [15]. 
Accumulating evidence points towards colonization and de novo infection. PJ colonization has been detected in 
16-29 % of patients with a variety of systemic autoimmune diseases [16,17] and Mori et al identified a cluster of 
de novo PCP infections in RA patients from a single outpatient clinic over a 2-year period [18]. Risk factors for 
PJ colonization include age over 60, chronic pulmonary disease, smoking, low absolute lymphocytes and CD4 
cells count, low serum immunoglobulins levels, use of corticosteroids (both its recent administration and daily 
dose of prednisolone over 15 mg) and methotrexate [16,17]. Even though none of these risk factors appear 
specific [16], age was the strongest contributor [17]. In a study by Mekinian et al, none of the patients with a 
systemic autoimmune disease and PJ colonization disease developed PCP, possibly due to the rapid decrease of 
the corticosteroid dose [16]. On the other hand in another study, 3 out of 9 RA patients with PJ colonization 
developed PCP 1 month after PCR identification even though these patients used low corticosteroids and 
methotrexate doses [19].  
In a murine model, B cells play an antibody-independent role in clearance of Pneumocystis carinii f. sp. muris 
through antigen presentation to CD4 T cells [20]. B cells seem to be required for the generation of CD4 effector 
cells capable of migrating to the lungs as well as for the expansion and generation of memory CD4 cells [20]. In 
order to identify the risk of PCP due to RTX, we reviewed the literature in patients with haematological 
malignancies, solid-organ transplantation and AAV.  
 
In haematological malignancies, a meta-analysis of randomized controlled trials identified patients with 
acute lymphoblastic leukaemia and allogeneic bone marrow transplant at increased risk for PCP and in need for 
prophylaxis [6]. Recent clinical observations suggest this association with PCP is related to RTX based treatment 
regimens [3]. The incidence of PCP is increased in patients receiving biweekly RTX, cyclophosphamide, 
adriamycin, vincrisitine and prednisolone (R-CHOP-14) therapy compared to standard R-CHOP every 21 days 
[21], from 2% with standard R-CHOP [22] to 6-11% with R-CHOP-14 [21]. PCP develops usually after four 
cycles of R-CHOP [21-23] with a point prevalence of PCP increasing with the number of cycles [22]. The 
median time to PCP onset is respectively 102 days from the first R- CHOP and 19 days from the last R-CHOP 
[22]. Patients with absolute lymphocyte count < 1.0x10^9/L [21,24], CD4 cell count < 0.2 x10^9/L [23] before 
chemotherapy have a higher risk for PCP, but this association with low CD4 cell counts is not found in other 
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studies [25,26]. PCP chemoprophylaxis recommendations with the use of RTX in haematology are scarce and 
vary from routine PCP chemoprophylaxis in all patients receiving RTX regimens [23] to only patients receiving 
dose-dense therapy like R-CHOP-14 [21,25,26] and to not recommending routine chemoprophylaxis given  the 
unclear risk-benefit ratio [22]. 
In transplantation medicine, renal transplant recipients have an increased risk for PCP in the early post-
transplant period justifying the use of prophylaxis in the first 6-12 months after transplantation [6, 27]. However 
2 cases of late onset PCP have also been described in  where B cells counts at the time of PCP diagnosis were 
still low - respectively 0.01 and 0.05 x10^9/L –nearly 3 years after the administration of a single dose of RTX 
(500 mg) for humoral rejection [28].  
PCP complicating AAV patients following RTX treatment is not uncommon. At least 6 AAV patients 
(1.2%) treated with RTX developed PCP among 516 patients from different cohorts [9-14,29-32] and proved 
fatal in 2 patients. PCP occurred 2, 3 and 32 months after the last RTX infusion in 3 patients including ours 
[13,29]. Half of the patients have chronic renal disease [13,14]. Half of the patients receive RTX in monotherapy 
[13,14] while the others receive RTX in combination with other immunosuppressive drugs [29,31].  
A retrospective study from a single centre - Mayo Clinic Rochester between 1998 and 2011- identifies 
30 patients that developed PCP after RTX treatment: 90% have haematological malignancies and 10% are only 
treated with RTX [3]. The patients are mostly older male -73% male with a median age of 70 years – and 27% 
have chronic renal disease [3]. PCP occurs after a median of 4 RTX cycles and a mean of 77 days after its last 
administration [3]. Patients have low lymphocytes (0.38x10^9/L), CD4 (0.25x10^9/L ) and CD8 (0.77x10^9/L) 
counts at PCP onset with undetectable B cells count [3]. 
 
Some experts in AAV have recommended maintaining PCP chemoprophylaxis in patients treated with RTX for 
at least the duration of B cells depletion [33]. If the PCP incidence in AAV/GPA patients is close to 1%, this 
recommendation is not supported by the general principles of PCP chemoprophylaxis. Even though PCP 
chemoprophylaxis is effective and reduced the mortality rate from PCP, the risk for PCP must be over 3.5% to 
outweigh the side effects of chemoprophylaxis [6]. Others concerns are that neither primary nor secondary PCP 
chemoprophylaxis is perfect [3] and that bacterial resistance to TMP-SMX can occur [6].  
PJ screening from induced sputum before RTX could help identify patients in need of eradication [19] and long-
term prophylaxis [16].  However as the association between PJ colonization and PCP development is not very 
strong, it is still unclear if screening will decrease PCP incidence [16,19]. 
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PCP chemoprophylaxis should not be administered solely when immunosuppressive therapy is intensified or 
when patients had low cell counts. In GPA patients, PCP chemoprophylaxis is usually administered during 
escalation of therapy with CYC and prednisolone but there is no solid evidence how long PCP 
chemoprophylaxis should continue [7]. PCP can even occur after chemoprophylaxis is stopped after CYC 
discontinuation in patients only taking low daily oral dose of prednisolone [7]. CD4 cell count serves as a useful 
marker in HIV patients but no CD4 levels cut-off works well in non-HIV immune compromised patients [34]. 
Long-term corticosteroids use can lower CD4 cell count [34] and the CD4 cell count does not reflect the 
impairment of T-cell mediated immunity following prolonged B cell depletion by RTX.  
 
In summary, a thorough assessment of the patient’s net state of immunodeficiency before administering RTX 
can help stratify the risk for both colonization and PCP development. Risk factors to be considered are age, renal 
or lung involvement, previous infections due to T cell-mediated immunity dysfunction, blood tests 
(lymphocytopenia, low CD4 cell count and inverted ratio) and concomitant therapy. 
In the present case, the patient was an older male with GPA with lung and kidney disease that relapsed and was 
treated with an increased daily oral prednisolone dose and RTX. He had had previous Varicella-zoster infection 
as well episodes with CMV reactivation, low CD4 cell count and an inverted CD4/CD8 ratio. The patient was 
thus at increased risk for PJ colonization and PCP. Routine PCP chemoprophylaxis prescribed at RTX initiation 
and continued at least until B cells recovered might have prevented PCP. In such patients, PCP 
chemoprophylaxis could possibly be indicated indefinitely. 
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Table 

















WCC x10^9/L 2.5 7.0 8.2 5.4 8.3 6.5 
Lymphocytes 
x10^9/L 
NR NR 0.6 1.3 NR 1.4 
B cells 
x10^9/L 
NR NR NR 0.04 <0.01 0.02 
CD4 cells 
x10^9/L 
NR NR NR 0.26 0.16 0.36 
CD4/CD8 ratio NR NR NR 0.43 NR 0.45 
IgG g/L 3.5 5.7 8.3 10.6 5.6 8.3 
PR3-ANCA 
UI/L 
NR 11 41• 42• 147* 154† 
 
CD: cluster of differentiation; CYCIV: intravenous cyclophosphamide; ID: immunosuppressive drug; MMF: 
mycophenolate mofetil; NR: not reported; PCP: Pneumocystis pneumonia; PR3-ANCA: proteinase 3 anti-
neutrophil cytoplasmic antibody; RTX: rituximab; WBC: white cell count 
 
* PR3-ANCA was measured in a different hospital. 
• PR3-ANCA was measured in our hospital with conventional Elisa (Phadia GmbH): Normal ≤ 10 
†PR3-ANCA was measured in our hospital with high-sensitivity Elisa (Phadia GmbH): Normal ≤ 2 
  
